沃特世合并碧迪医疗业务后股价创新低，市场关注整合风险

Core Viewpoint - Waters Corporation's stock price significantly declined after completing the merger with BD's biosciences and diagnostics solutions business, reaching a 60-day low [1] Stock Performance - The merger was announced on February 9, 2026, and the stock price dropped by 13.94% on the first trading day, continuing to fluctuate, closing at $316.92 on February 12, down approximately 15.9% from $376.89 on February 5, with an intraday low of $305.35 [2] Financial Status - For fiscal year 2025, Waters reported a revenue increase of 6.99% year-over-year, with a slight net profit increase of 0.75%. However, Q4 revenue was $932 million, with a net profit decline of 2.67% year-over-year. The market is likely to focus on short-term integration costs and the realization of synergy effects, with an expected $2 billion in cost synergies over three years, although rising short-term expenses may pressure profit margins [3] Institutional Perspectives - Post-merger, several institutions updated their ratings with target prices ranging from $350 to $440. Citigroup and Barclays upgraded to "Buy," while Bank of America downgraded the target price to $350, maintaining a "Hold" rating, indicating market divergence regarding growth prospects post-merger. Trading volume significantly increased, averaging $1.14 billion from February 9 to 11, reflecting heightened capital divergence and potential stock price volatility [4] Future Development - Management emphasized that the merger will strengthen the company's position in high-growth areas such as biopharmaceuticals and diagnostics, with long-term goals of a 7% compound annual revenue growth rate and a 450 basis point expansion in profit margins. However, the market is currently more focused on integration risks and macroeconomic factors, such as interest rate policies affecting high-valuation sectors, leading to a divergence between stock price and long-term fundamentals [5]